# Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis

> **NCT03231033** · PHASE1 · COMPLETED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 3 (actual)

## Conditions studied

- Autoimmune Pulmonary Alveolar Proteinosis

## Interventions

- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT03231033
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-17
- **Primary completion:** 2019-04-02
- **Final completion:** 2019-04-02
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03231033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03231033, "Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03231033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*